Jason Gentle

Jason joined LifeSci in July 2022 and has built broad experience across commercial strategy, corporate development, and strategic partnering engagements in the life sciences industry. His work includes commercial opportunity assessments, asset valuation, indication prioritization, and commercial due diligence across therapeutic areas including immunology, oncology, rare disease, dermatology, and ophthalmology.

Prior to LifeSci, Jason interned at a biotechnology startup, where he utilized bioinformatic data to support the development of cancer proteomic databases. Jason earned a B.S. in Molecular and Medical Microbiology and a B.A. in Economics from the University of California, Davis.